Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Artichoke Whole Phytocomplex Concentrate (AWPC) is a standardized, freeze-dried extract of artichoke (Cynara scolymus) leaves developed by ABOCA and evaluated by the Ontario Clinical Oncology Group (OCOG). It is primarily investigated as a chemoprevention agent for malignant pleural mesothelioma in high-risk populations, such as individuals with asbestos-related lung or pleural disease. The extract is rich in bioactive compounds, including caffeoyl quinic acids, chlorogenic acid, and cynaropicrin. Its mechanism of action involves the induction of apoptosis, inhibition of cell proliferation, and reduction of cell invasion. In clinical trials, AWPC is monitored for its impact on biomarkers like serum mesothelin and specific microRNAs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Artichoke Whole Phytocomplex Concentrate.